Albuminuria News and Research

RSS

Albuminuria also called proteinuria or urine albumin—is a condition in which urine contains an abnormal amount of protein. Albumin is the main protein in the blood. Proteins are the building blocks for all body parts, including muscles, bones, hair, and nails. Proteins in the blood also perform a number of important functions. They protect the body from infection, help blood clot, and keep the right amount of fluid circulating throughout the body.

New evidence shows particulate matter exposure associated with kidney damage

Many first responders working at Ground Zero following the 9/11 tragedy were exposed to cement dust, smoke, glass fibers, and heavy metals. Exposure to high levels of such particulate matter caused significant damage to first responders' kidneys, according to research presented at ASN Kidney Week 2013 November 9 at the Georgia World Congress Center in Atlanta, GA.

11 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Urinary protein may be early warning sign regarding patients' cognitive abilities

The presence of protein in the urine may be a marker of risk for future cognitive decline in patients with type 2 diabetes and normal kidney function, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

30 Aug 2013

High levels of urinary albumin-to-creatinine ratio linked with greater risk of CHD in black individuals

In a large national study, higher levels of the urinary albumin-to-creatinine ratio was associated with greater risk of incident but not recurrent coronary heart disease in black individuals when compared with white individuals, according to a study in the August 21 issue of JAMA.

21 Aug 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

CKD may raise risk of mortality and end stage renal disease for both men and women

A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.

31 Jan 2013

BPA adversely affects kidney function in children

Children with high levels of exposure to bisphenol A are at increased risk for low-grade albuminuria, report researchers.

16 Jan 2013

CYP2J2 implicated in preeclampsia

Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.

11 Dec 2012

CYP2J2 implicated in preeclampsia

Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.

10 Dec 2012

Modified CKD model aids risk prediction in African Americans

Screening African Americans for microalbuminuria at either 5- or 10-year intervals would be highly cost-effective using a modified version of the CKD Health Policy Model, US researchers report.

7 Dec 2012

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.

5 Dec 2012

Kidney disease measures on mortality, ESRD unaffected by age

Regardless of age, estimated glomerular filtration rate and high albuminuria are linked to death and end-stage renal disease, say US scientists who found a lower relative but higher absolute mortality risk difference at older age.

23 Nov 2012

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

3 Nov 2012